Abstract
In 1960, it was discovered that Simian Virus 40 (SV40) contaminated up to 30% of the poliovirus vaccines in the US. This contamination arose because the vaccines were produced in monkey kidney cell cultures harboring SV40 between 1955 and 1963. During this period, approximately 90% of children and 60% of adults in the USA were inoculated for polio and possibly exposed to SV40. Many epidemiologic and molecular pathogenesis studies have been conducted in order to identify potential cancer risks since this ‘natural’ experiment began. Productive SV40 infection has the potential to initiate malignancy in a variety of target tissues. Epidemiological studies that investigated the relationship between SV40 infection and cancer risks have yielded mixed results. Studies can be grouped into three categories based on their exposure definition of SV40 infection: (1) use of vaccination or birth cohorts as proxy variables for infection, (2) follow-up of children of pregnant women who received polio vaccines, and (3) direct molecular detection of the virus or serologic detection of anti-SV40 antibody responses. A meta-analysis of five published studies did not support the hypothesis that SV40 exposure increases the overall risk of cancer incidence or cancer mortality. The analysis of specific cancer sites is largely inconclusive because of substantial problems that most studies have had in reliably defining exposure, defining latency effects, or dealing with confounding and other biases. A new generation of molecular epidemiologic studies is necessary to properly address these issues.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Butel J and Lednicky J . (1999). J. Natl. Cancer Inst., 91, 119–134.
Carbone M, Pass HI, Miele L and Bocchetta M . (2003). Oncogene, 22, 5173–5180.
Carbone M, Rizzo P and Pass H . (2000). Anticancer Res., 20, 875–877.
Carbone M, Rizzo P and Pass HI . (1997). Oncogene, 15, 1877–1888.
Carroll-Pankhurst C, Engels EA, Strickler HD, Goedert JJ, Wagner J and Mortimer Jr EA . (2001). Br. J. Cancer, 85, 1295–1297.
Carter JJ, Madeleine MM, Wipf GC, Garcea RL, Pipkin PA, Minor PD and Galloway DA . (2003). J. Natl. Cancer Inst., 95, 1522–1530.
Cerrano PG, Jasani B, Filiberti R, Neri M, Merlo F, De Flora S, Mutti L and Puntoni R . (2003). Int. J. Oncol., 22, 187–194.
Eddy BE, Borman GS, Grubbs GE and Young RD . (1962). Virology, 17, 65–75.
Engels EA, Katki HA, Nielsen NM, Winther JF, Hjalgrim H, Gjerris F, Rosenberg PS and Frisch M . (2003a). J. Natl. Cancer Inst., 95, 532–539.
Engels EA, Rodman LH, Frisch M, Goedert JJ and Biggar RJ . (2003b). Int. J. Cancer., 106, 283–287.
Farwell JR, Dohrmann GJ, Marrett LD and Meigs JW . (1979). Trans. Am. Neurol. Assoc., 104, 261–264.
Fisher SG, Weber L and Carbone M . (1999). Anticancer Res., 19, 2173–2180.
Fraumeni Jr JF, Ederer F and Miller RW . (1963). JAMA, 185, 713–718.
Gazdar AF, Butel JS and Carbone M . (2002). Nat. Rev. Cancer, 2, 957–964.
Heinonen OP, Shapiro S, Monson RR, Hartz SC, Rosenberg L and Slone D . (1973). Int. J. Epidemiol., 2, 229–235.
Innis MD . (1968). Nature, 219, 972–973.
IOM Report (2002) Stratton K, Almario DA and McCormick M (eds). Immunization Safety Review. SV40 Contamination of Poliovaccine and Cancer. The National Academy of Sciences: Washington, DC.
Jensen F, Koprowski H, Pagano JS, Ponten J and Ravdin RG. (1964). J. Natl. Cancer Inst., 32, 917–937.
Kirschtein RL and Gerber P . (1962). Nature, 195, 299–300.
Mortimer Jr EA, Lepow ML, Gold E, Robbins FC, Burton GJ and Fraumeni Jr JF . (1981). N. Engl. J. Med., 305, 1517–1518.
Procopio A, Strizzi L, Vianale G, Betta P, Puntoni R, Fontana V, Tassi G, Gareri F and Mutti L . (2000). Genes Chromosomes Cancer, 29, 173–179.
Puntoni R, Filiberti R, Cerrano PG, Neri M, Andreatta R and Bonassi S . (2003). Mutat. Res., 544, 385–396.
Rollison DE, Helzlsouer KJ, Alberg AJ, Hoffman S, Hou J, Daniel R, Shah KV and Major EO . (2003). Cancer Epidemiol. Biomarkers Prev., 12, 460–463.
Shah K and Nathanson N . (1976). Am. J. Epidemiol., 103, 1–12.
Strickler HD, Rosenberg PS, Devesa SS, Hertel J, Fraumeni Jr JF and Goedert JJ . (1998). JAMA, 279, 292–295.
Strickler HD, Rosenberg PS, Devesa SS, Fraumeni Jr JF and Goedert JJ . (1999). Med. Pediatr. Oncol., 32, 77–78.
Sweet BH and Hilleman MR . (1960). Proc. Soc. Exp. Biol. Med., 105, 420–427.
Testa JR, Carbone M, Hirvonen A, Khalili K, Krynska B, Linnainmaa K, Pooley FD, Rizzo P, Rusch V and Xiao GH . (1998). Cancer Res., 58, 4505–4509.
Acknowledgements
We are grateful to Professor Michele Carbone, Loyola University, for valuable technical comments and editorial advice. Mr Tam Dang-Tan and Professor Eduardo L Franco are recipients of Doctoral Fellowship and Distinguished Scientist awards, respectively, from the Canadian Institutes of Health Research.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dang-Tan, T., M Mahmud, S., Puntoni, R. et al. Polio vaccines, Simian Virus 40, and human cancer: the epidemiologic evidence for a causal association. Oncogene 23, 6535–6540 (2004). https://doi.org/10.1038/sj.onc.1207877
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207877
Keywords
This article is cited by
-
Role of BK human polyomavirus in cancer
Infectious Agents and Cancer (2018)
-
Epidemiology of SV-40 Simian Virus in Different Regions of the Russian Federation
Bulletin of Experimental Biology and Medicine (2009)
-
A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes
Nature Reviews Cancer (2007)
-
Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins
Oncogene (2006)